benzyl (6-oxohexyl)carbamate | 98648-05-6

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (6-oxohexyl)carbamate
• 英文别名: Benzyl 6-oxohexylcarbamate；benzyl N-(6-oxohexyl)carbamate
• CAS: 98648-05-6
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: XPGMGPSEWHRDSL-UHFFFAOYSA-N

物化性质

• 沸点：
  412.7±38.0 °C(Predicted)
• 密度：
  1.079±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  benzyl (6-oxohexyl)carbamate 在 palladium on activated charcoal 氢气 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 10-(6-amino-hexyl)-1,4,7,10-tetraaza-cyclododecane-1,4,7-tricarboxylic acid tri-tert-butyl ester
  参考文献：
  名称：

  Effective Methods for the Biotinylation of Azamacrocycles

  摘要：

  The biotin-(strept)avidin interaction remains a gold standard of model biological recognition events. The biotinylation of azarnacrocycles permits the investigation of signal transduction between this recognition event and the metal center of an azamacrocycle complex, of wide potential interest in biosensing. There are no generally applicable procedures in the literature for such functionalizations. We report here a comprehensive investigation into the attachment of biotin to TACN, cyclen, and cyclam.. Effective methods have been found for each ring. The efficacy of the functionalization is critically dependent on the nature of the azarnacrocycle.

  DOI：

  10.1021/jo071175v
• 作为产物：
  描述：

  7-氨基-4-氯-3-甲氧基异香豆素 在 lithium aluminium tetrahydride 、 氯化亚砜 、 碳酸氢钠 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 为溶剂， 生成 benzyl (6-oxohexyl)carbamate
  参考文献：
  名称：

  Further characterization of a putative serine protease contributing to the γ-secretase cleavage of β-amyloid precursor protein

  摘要：

  The 3-alkoxy-7-amino-4-chloro-isocoumarins JLK-6 and JLK-2 have been shown to markedly reduce the production of Amyloid beta-peptide (A beta) by Amyloid-beta Precursor Protein (APP) expressing HEK293 cells by affecting the gamma-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor. This suggested that these compounds do not directly inhibit the presenilin-dependent gamma-secretase complex but more likely interfere with an upstream target involved in gamma-secretase-associated pathway. The mechanism of action of these compounds is unknown and there are high fundamental and therapeutical interests to unravel their target. Isocoumarin compounds were previously shown to behave as potent mechanism-based irreversible inhibitors of serine proteases, suggesting that the JLK-directed target could belong to such enzyme family. To get further insight into structure-activity relationships and to develop more potent isocoumarin derivatives, we have synthesized and evaluated a series of isocoumarin analogues with modifications at positions 3, 4 and 7. In particular, the 7-amino group was substituted with either acyl, urethane, alkyl or aryl groups, which could represent additional interaction sites. Altogether, the results highlighted the essential integrity of the 3-alkoxy-7-amino-4-chloro-isocoumarin scaffold for A beta-lowering activity and supported the involvement of a seri ne protease, or may be more generally, a serine hydrolase. The newly reported 7-N-alkyl series produced the most active compounds with an IC50 between 10 and 30 mu M. Finally, we also explored peptide boronates, a series of reversible serine protease inhibitors, previously shown to also lower cellular A beta production. The presented data suggested they could act on the same target or interfere with the same pathway as isocoumarins derivatives. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.11.045

文献信息

• Highly Chemoselective Aerobic Oxidation of Amino Alcohols into Amino Carbonyl Compounds
  作者：Yusuke Sasano、Shota Nagasawa、Mai Yamazaki、Masatoshi Shibuya、Jaiwook Park、Yoshiharu Iwabuchi

  DOI：10.1002/anie.201309634

  日期：2014.3.17

  direct oxidation of unprotected amino alcohols to their corresponding amino carbonyl compounds has often posed serious challenges in organic synthesis and has constrained chemists to adopting an indirect route, such as a protection/deprotection strategy, to attain their goal. Described herein is a highly chemoselective aerobic oxidation of unprotected amino alcohols to their amino carbonyl compounds

  未保护的氨基醇直接氧化成其相应的氨基羰基化合物经常在有机合成中面临严峻挑战，并限制了化学家采用间接路线（例如保护/脱保护策略）来实现其目标。本文描述了未保护的氨基醇对它们的氨基羰基化合物的高度化学选择性好氧氧化，其中使用了2-氮杂金刚烷N-氧基（AZADO）/铜催化。所开发的催化系统导致带有伯，仲或叔氨基的各种未保护氨基醇的醇选择性氧化，在环境温度下暴露于空气下具有良好至高收率，从而为合成氮提供了灵活性。含有化合物。
• NEW ANTIBODY DRUG CONJUGATES (ADCS) AND THE USE THEREOF
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150023989A1

  公开（公告）日：2015-01-22

  The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

  本申请涉及针对FGFR2靶点的新抗体药物结合物（ADCs），所述ADCs的药物代谢产物，生产所述ADCs的方法，利用所述ADCs治疗和/或预防疾病以及利用所述ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病如癌症。这种治疗可以作为单药疗法进行，也可以与其他药物或额外的治疗措施结合使用。
• NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME
  申请人：SEATTLE GENETICS, INC.

  公开号：US20150246136A1

  公开（公告）日：2015-09-03

  The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures.

  本专利申请涉及针对靶向表皮生长因子受体（EGFR，基因ID 1956）的新型结合物-药物共轭物（ADCs）N，N-二烷基月桂酰基蛋白酶抑制剂，这些ADCs的有效代谢物，生产这些ADCs的方法，利用这些ADCs治疗和/或预防疾病，以及利用这些ADCs生产用于治疗和/或预防疾病的药物，特别是治疗高增殖和/或血管生成性疾病，如癌症。这种治疗可以作为单药疗法或与其他药物或其他治疗措施联合使用。
• 4-substituted 2-aminoalk-3-enoic acids
  申请人：Ciba-Geigy Corp.

  公开号：US05294734A1

  公开（公告）日：1994-03-15

  Substituted 2-aminoalk-3-enoic acid derivative of formula I ##STR1## wherein R.sub.1 is an aliphatic hydrocarbon radical that is substituted by optionally acylated or aliphatically or araliphatically etherified hydroxy, by halogen, by optionally acylated and/or aliphatically substituted amino or by an aza-, diaza-, azoxa- or oxa-cycloaliphatic radical, or is an oxacycloaliphatic hydrocarbon radical bonded via a carbon atom, or is an optionally aliphatically N-substituted or N-acylated azacycloaliphatic hydrocarbon radical, and R.sub.2 is free or esterified carboxy, and their salts exhibit NMDA-antagonistic properties and are useful as active ingredients of anticonvulsive medicaments.

  取代的2-氨基烷基-3-烯酸衍生物的公式I ##STR1## 其中R.sub.1是一个被取代的脂肪烃基团，可以通过选择性地酰化或脂肪族或芳脂肪族醚化的羟基，通过卤素，通过选择性地酰化和/或脂肪族取代的氨基，或者通过一个aza-，diaza-，azoxa-或oxa-环脂肪族基团，或者是一个通过碳原子连接的氧杂环脂肪烃基团，或者是一个选择性地脂肪族N-取代或N-酰化的氮杂环脂肪烃基团，并且R.sub.2是自由的或酯化的羧基，它们的盐类具有NMDA-拮抗性质，并且作为抗惊厥药物的有效成分是有用的。
• Metal-free one-pot α-carboxylation of primary alcohols
  作者：Gydo van der Heijden、Jasper Kraakman、Jasper Biemolt、Eelco Ruijter、Romano V. A. Orru

  DOI：10.1039/c6ob01813k

  日期：——

  An efficient metal-free procedure for the formal α-carboxylation of primary alcohols has been developed. The method involves a one-pot oxidation/Passerini/hydrolysis sequence and provides access to α-hydroxy acids bearing a broad range of functional groups. A minor modification to the reaction conditions extends the range of accessible products to α-hydroxy esters.

  已经开发出一种有效的无金属的伯醇形式α-羧化方法。该方法涉及一锅氧化/ Passerini /水解顺序，并提供了带有多种官能团的α-羟基酸的通道。对反应条件的微小改动将可及产品的范围扩展至α-羟基酯。